NIKKEI 225
26,911.20 +251.45 (+0.94%) HANG SENG
20,644.28 +41.76 (+0.20%) CRUDE OIL
109.48 -2.92 (-2.60%) GOLD FUTURES
1,816.40 -2.50 (-0.14%) DOW
31,529.11 -1,125.48 (-3.45%) BTC-GBP
23,572.66 -588.45 (-2.44%)
Novo Nordisk A/S (NOVO-B.CO)
| Previous close | 748.80 |
| Open | 750.10 |
| Bid | 738.90 x 0 |
| Ask | 742.90 x 0 |
| Day's range | 737.20 - 755.00 |
| 52-week range | 475.45 - 834.50 |
| Volume | |
| Avg. volume | 2,075,988 |
| Market cap | 1.684T |
| Beta (5Y monthly) | 0.32 |
| PE ratio (TTM) | 34.55 |
| EPS (TTM) | 21.50 |
| Earnings date | N/A |
| Forward dividend & yield | 10.40 (1.39%) |
| Ex-dividend date | 25 Mar 2022 |
| 1y target est | 784.25 |
- Globe Newswire
Novo Nordisk A/S: Share repurchase programme
Bagsværd, Denmark, 16 May 2022 – On 3 May 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 24 billion to be executed during a 12-month period beginning 2 February 2022. Under the programme initiate
- Zacks
Lilly's (LLY) Diabetes Treatment Tirzepatide Gets FDA Nod
Lilly's (LLY) Mounjaro (tirzepatide) is a novel diabetes treatment, which has shown impressive blood sugar reductions and weight loss in a broad range of type II diabetes patients in the SURPASS studies.
- Stockopedia
Assessing the impact of economic shocks on the Novo Nordisk A/S share price
A question on the minds of many investors right now is how economic uncertainty will continue to affect large cap companies, such as Novo Nordisk A/S (CPH:NOVO...
